Medicinal Cannabis Merger Risks: Can LGP and Cannatrek Deliver on Synergies?

A Market-Shaping Merger in Medicinal Cannabis

Little Green Pharma Ltd (LGP) has announced a proposed acquisition of Cannatrek Ltd through a scheme of arrangement, marking a significant consolidation in the Australian medicinal cannabis sector. This merger combines two of the country's largest and most successful medicinal cannabis companies, positioning the combined entity as a global leader with a vertically integrated supply chain spanning cultivation, manufacturing, distribution, and digital health platforms.

The transaction is structured to issue new LGP shares and contingent value (CV) shares to Cannatrek shareholders, resulting in an initial ownership split of approximately 60.5% for Cannatrek and 39.5% for existing LGP shareholders. The CV shares provide a mechanism to adjust ownership based on future liabilities, potentially increasing Cannatrek’s stake by up to 8%. Both parties’ key shareholders will be subject to staged voluntary escrow arrangements to ensure alignment and stability post-merger.

Strategic Rationale and Synergies

The merger is designed to deliver immediate scale benefits, tripling LGP’s standalone revenue to a combined pro-forma FY25 revenue of AUD 112.3 million and boosting adjusted EBITDA to AUD 13.0 million. Cannatrek’s robust balance sheet and strong cash position underpin the group’s ambitions to expand its Danish cultivation facility and accelerate growth across European markets.

Operational synergies are expected from leveraging Cannatrek’s GMP-certified manufacturing capabilities in Australia alongside LGP’s latent manufacturing capacity in Denmark. This vertical integration will reduce per-unit production costs and enhance margin capture across the supply chain. Additionally, combining clinic operations and digital health platforms such as Greenship and MyEden strengthens patient connectivity and distribution efficiency.

Market Context and Growth Prospects

The medicinal cannabis markets in Australia and Europe are maturing rapidly, with increasing regulatory clarity and market consolidation favouring larger, vertically integrated players. Australia’s medicinal cannabis market is projected to surpass AUD 1 billion in sales by 2026, while Europe’s market is forecast to grow at a compound annual growth rate of over 30% through 2032, driven by countries like Germany, France, and Spain.

By controlling the entire patient journey from seed to sale, the combined group aims to build a competitive moat that smaller, fragmented players cannot easily replicate. The merger also positions the company to benefit from evolving regulatory frameworks, including anticipated reforms in Australia and ongoing developments in European markets.

Next Steps and Approvals

The merger remains subject to customary conditions precedent, including regulatory and court approvals, shareholder votes, and an independent expert’s report confirming the scheme is in shareholders’ best interests. The timetable targets key milestones such as the first court hearing in early March 2026, dispatch of the Scheme Booklet in March, shareholder meetings in April, and implementation by 1 May 2026.

Both Cannatrek’s and LGP’s boards have expressed unanimous support for the transaction, contingent on no superior proposals emerging. The combined entity is expected to attract increased institutional investor interest and improved analyst coverage, potentially driving a valuation uplift and re-rating.